|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | High-Efficiency Genome Editing in Arabidopsis Using YAO Promoter-Driven CRISPR/Cas9 System显示文摘 | Yan, Liuhua Wei, Shaowei Wu, Yaorong Hu, Ruolan Li, Hongju Yang, Weicai Xie, Qi | 2015 | Molecular Plant2015，8，12： | 50 |
| 2 | A theoretical and experimental investigation of the size distribution of polystyrene microspheres by seeded polymerization显示文摘 | Qi Zhang Yan Han Weicai Wang | | 0，，01： | 1 |
| 3 | Direct recursion of the ratio of Bessel functions with applications to Mie scattering calculations 显示文摘 | Wei WeiCai Yan Zhao Lin Ma | 2008 | Journal of Quantitative Spectroscopy & Radiative Transfer2008，109，： | 1 |
| 4 | A theoretical and experimental investigation of the size distribution of polystyrene microspheres by seeded polymerization显示文摘 | Qi Zlaang Yan Han Weicai Wang | 2010 | Journal of Colloid and Interface Science2010，342，1： | 1 |
| 5 | Morphology and microstructure of core-shell hybrid latexes containing fluoropolymer and acrylic copolymer 显示文摘 | Chen Su Yan Weicai Chen Li | 2006 | Colloid Polymer Science2006，284，4： | 1 |
| 6 | Morphology and microstructure of core-shell hybrid latexes containing fluoropolymer and acrylic copolymer显示文摘 | Chen Su Yan Weicai Chen Li | 2006 | Colloid Polymer Science2006，284，4： | 1 |
| 7 | Morphology and microstructure of core-shell hybrid latexes containing fluoropolymer and acrylic copolymer 显示文摘 | Su Chen Weicai Yan Li Chen | 2006 | Colloid Polym Sci2006，284，： | 1 |
| 8 | 查看详情显示文摘 | Chen Su Yan Weicai Chen Li | | 0，，4： | 1 |
| 9 | Advances in Arabidopsis research in China from 2006 to 2007显示文摘Arabidopsis thaliana,模型植物种,由于许多作为一个试验性的有机体比另外的植物种类有很多个优点它的基因并且 genomic 特征。TheChinese Arabidopsis 社区做了重要贡献在 recentyears~ 种生物学研究([1,2 ]) 。在 2006,在中国的植物生物学的研究以前比平常收到了更多的注意,特别那些与 Arabidopsis 研究相关。这里,我们简短在中国总结最近的进展 inArabidopsis 研究。 | LIANG Yan ZUO JianRu YANG WeiCai | 2007 | Chinese Science Bulletin2007，52，13： | 0 |
| 10 | Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma:Results of a prospective randomized study显示文摘Background:Chemotherapy plus granulocyte colony-stimulating factor (GCSF) regimen is one of the available approaches to mobilize peripheral blood progenitor cells (PBPCs).It causes thrombocytopenia and delays leukapheresis.This study aimed to evaluate the role of recombinant human thrombopoietin (rhTPO) before mobilization chemotherapy in facilitating leukapheresis in patients with lymphoma.Methods:In this randomized open-label phase 2 trial, patients were randomly assigned in a 1:2 ratio to receive mobilization with rhTPO plus GCSF in combination with chemotherapy (the rhTPO plus GCSF arm) or GCSF alone in combination with chemotherapy (the GCSF alone arm).The recovery of neutrophils and platelets and the amount of platelet transfusion were monitored.Results:Thirty patients were enrolled in this study between March 2016 and August 2018. Patients in the rhTPO plus GCSF arm (n = 10) had similar platelet nadir after mobilization chemotherapy (P=0.878) and similar amount of platelet transfusion (median 0 vs.1 unit,P=0.735) when compared with the GCSF alone arm (n = 20). On the day of leukapheresis, the median platelet count was 86 ×10^(9)/L (range 18-219) among patients who received rhTPO and 73 ×10^(9)/L (range 42-197) among those who received GCSF alone (P=0.982). After the use of rhTPO, the incidence of platelet count <75 ×10^(9)/L on the day of leukapheresis did not decrease significantly (30.0% vs. 50.0%,P=0.297).Platelet recovery after PBPC transfusion was more rapid in the rhTPO plus GCSF arm (median 8.0 days [95% confidence interval 2.9-13.1] to platelets ≥50 ×10^(9)/L vs. 11.0 days [95% confidence interval 8.6-13.4],P=0.011).The estimated total cost of the mobilization and reconstitution phases per patient was similar between the two treatmtent groups (P=0.362 andP=0.067,respectively).Conclusions:Our findings indicate that there was no significant clinical benefit of rhTPO use in facilitating mobilization of progenitor cells,but it may promote platelet recovery in the reconstitution phase after high-dose therapy.Trial registration:This trial has been registered in Clinicaltrials.gov as NCT03014102. | Hongnan Mo Peng Liu Yan Qin Xiaohui He Xiaohong Han Jiarui Yao Weicai Su Shuxiang Zhang Le Tang Fengyi Zhao Lin Gui Sheng Yang Jianliang Yang Shengyu Zhou Zhishang Zhang Yuankai Shi | 2021 | Chronic Diseases and Translational Medicine2021，7，3： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员